This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guan, R. Articles by Luo, Y. Search for Related Content PubMed PubMed Citation Articles by Guan, R. Articles by Luo, Y.

Small Interfering RNA–Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals

Departments ¹ R47S and ² R47J, Cancer Research, Abbott Laboratories, Abbott Park, Illinois

Requests for reprints: Yan Luo, Department R47S, Cancer Research, Abbott Laboratories, 100 Abbott Park Road, AP9A, Abbott Park, IL 60064. Phone: 847-935-6811; Fax: 847-938-2365; E-mail: yan.luo{at}abbott.com.

Polo-like kinase 1 (Plk1) is required for multiple stages of mitosis and is up-regulated in many human malignancies. We depleted Plk1 expression using small interfering RNA (siRNA) and showed defects in bipolar spindle formation and cytokinesis, growth inhibition, and apoptosis induction in human cancer cell lines. To our surprise, depletion of Plk1 in normal human cells did not result in obvious cell cycle defects, and did not induce significant inhibition of cell growth for at least two cell cycles. In addition, Plk1 siRNA inhibited colony formation in soft agar and tumorigenesis in a HT1080 xenograft model in a dose-dependent manner. Analysis with isogenic pairs of cell lines, differing in p53 status, revealed that Plk1 depletion preferentially induced mitotic arrest, aneuploidy, and reduced cell survival in the p53-defective cell lines. No obvious defects were observed in most p53 wild-type cells during the first few cell cycles. In addition, long-term survival studies revealed that p53 facilitates survival upon Plk1 depletion. Therefore, short-term inhibition of Plk1 can kill tumor cells while allowing normal cells to survive. These data validate the episodic inhibition of Plk1 as a very useful approach for cancer treatment.

Key Words: Plk1 • siRNA • mitosis • p53 • cancer

This article has been cited by other articles:

				J. Fink, K. Sanders, A. Rippl, S. Finkernagel, T. L. Beckers, and M. Schmidt Cell type dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines Mol. Cancer Ther., December 1, 2007; 6(12): 3189 - 3197. [Abstract] [Full Text] [PDF]

				A. Morozov, S. J. Lee, Z.-K. Zhang, V. Cimica, D. Zagzag, and G. V. Kalpana INI1 Induces Interferon Signaling and Spindle Checkpoint in Rhabdoid Tumors Clin. Cancer Res., August 15, 2007; 13(16): 4721 - 4730. [Abstract] [Full Text] [PDF]

				T. J. Lansing, R. T. McConnell, D. R. Duckett, G. M. Spehar, V. B. Knick, D. F. Hassler, N. Noro, M. Furuta, K. A. Emmitte, T. M. Gilmer, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 Mol. Cancer Ther., February 1, 2007; 6(2): 450 - 459. [Abstract] [Full Text] [PDF]

				S. Kappel, Y. Matthess, B. Zimmer, M. Kaufmann, and K. Strebhardt Tumor inhibition by genomically integrated inducible RNAi-cassettes Nucleic Acids Res., September 11, 2006; 34(16): 4527 - 4536. [Abstract] [Full Text] [PDF]

				M. Schmidt, H.-P. Hofmann, K. Sanders, G. Sczakiel, T. L. Beckers, and V. Gekeler Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells. Mol. Cancer Ther., April 1, 2006; 5(4): 809 - 817. [Abstract] [Full Text] [PDF]

				X. Liu, M. Lei, and R. L. Erikson Normal cells, but not cancer cells, survive severe plk1 depletion. Mol. Cell. Biol., March 1, 2006; 26(6): 2093 - 2108. [Abstract] [Full Text] [PDF]